ClinicalTrials.gov
ClinicalTrials.gov Menu

A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft Tissue

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01719172
Recruitment Status : Completed
First Posted : November 1, 2012
Results First Posted : February 27, 2014
Last Update Posted : February 27, 2014
Sponsor:
Information provided by (Responsible Party):
Medtronic - MITG

Brief Summary:
The objective of this study is to determine the safety of Veriset™ Hemostatic Patch when used during non-emergent, open, soft tissue surgery where a topical hemostatic agent would be used.

Condition or disease Intervention/treatment Phase
Non-emergent, Soft Tissue Procedures, Performed Via an Open Approach Device: Veriset™ Hemostatic Patch Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft Tissue
Study Start Date : September 2012
Actual Primary Completion Date : May 2013
Actual Study Completion Date : June 2013

Arm Intervention/treatment
Experimental: Veriset™ Hemostatic Patch
Topical hemostat
Device: Veriset™ Hemostatic Patch
Topical Hemostat



Primary Outcome Measures :
  1. Percent Success in Obtaining Hemostasis Following Veriset Hemostatic Patch Treatment [ Time Frame: Intra-operative (Day 0) ]
    Success will be defined as hemostasis obtained within 5 minutes. Hemostasis will be assessed every 30 seconds until the 5-minute time point, at which point the visual inspection will continue at one-minute intervals up to 10 minutes or until hemostasis is achieved.


Secondary Outcome Measures :
  1. Proportion of Subjects Who Achieve Hemostasis Within 1 Minute [ Time Frame: Intra-operative (Day 0) ]
    Hemostasis will be assessed every 30 seconds until the 5-minute time point, at which point the visual inspection will continue at one-minute intervals up to 10 minutes or until hemostasis is achieved.

  2. Median Time to Achieve Hemostasis [ Time Frame: Intra-operative (Day 0) ]
    Hemostasis will be assessed every 30 seconds until the 5-minute time point, at which point the visual inspection will continue at one-minute intervals up to 10 minutes or until hemostasis is achieved.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject or authorized representative has provided informed consent.
  • Subject is ≥ 18 years old.
  • Subject is scheduled for nonemergent surgery where a topical hemostatic agent would be used to control bleeding emanating from a tissue bed following organ dissection or removal or a bleeding tumor tissue bed following resection or dissection, via an open approach.
  • Subject is willing and able to comply with all aspects of the treatment and evaluation schedule.
  • Subject has an appropriate Target Bleeding Site (TBS) during the surgical procedure.
  • TBS bleeding assessment is Type 2 or 3 (refer to table in protocol).

Exclusion Criteria:

  • Subject is pregnant (documented by a positive pregnancy test) or is actively breast-feeding.
  • Subject has an estimated life expectancy of less than 6 months.
  • Subject is scheduled for another planned surgery and the subsequent surgery would jeopardize the previous application of study treatment.
  • Subject is undergoing emergency surgery, i.e. lifesaving procedures performed where patient is in imminent danger of death.
  • Subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with the study.
  • Subject has an active local infection at the TBS.
  • The investigator determines that participation in the study may jeopardize teh safety or welfare of the subject.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01719172


Locations
Austria
Innsbruck, Austria
Germany
Hannover, Germany
München, Germany
Sponsors and Collaborators
Medtronic - MITG

Responsible Party: Medtronic - MITG
ClinicalTrials.gov Identifier: NCT01719172     History of Changes
Other Study ID Numbers: COVEUST0278
First Posted: November 1, 2012    Key Record Dates
Results First Posted: February 27, 2014
Last Update Posted: February 27, 2014
Last Verified: January 2014

Additional relevant MeSH terms:
Hemostatics
Coagulants